Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

2025 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 18 Studies for 5 Innovative Products

Simcere Zaiming Announces Phase 3 Clinical Trial Results for Cetuximab β Injection (Enlituo)

Simcere Zaiming will present 7 innovative researches at the 2025 AACR

Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA

NDA of Deunoxavir Marboxil ,the Next Generation Innovative Influenza Drug get Accepted , Offering Hope for "One-Pill Cure" for Influenza.

All Patients Enrolled in Phase III Clinical Study of Deunoxavir Marboxil for Pediatric Indication

Simcere Pharmaceutical and Fermion Technology Collaborate to Develop China's First SSTR4-Targeting Analgesic

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SIM0505, an ADC candidates Simcere Zaiming developed using proprietary technology platform, is entering trials both in China and the USA